Skip to content

Assessment of AI Program 'DRISTi' as a Screening Tool

Assessment of 'DRISTi' as an Automated Diabetic Retinopathy Screening Tool in Diabetic Populations

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07222293
Enrollment
900
Registered
2025-10-29
Start date
2025-11-23
Completion date
2026-03-31
Last updated
2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy (DR)

Keywords

Artificial Intelligence, Ophthalmic Device, AI, Diabetic Retinopathy, Diabetes, DR, Screening, Online/Offline, Fundus Camera

Brief summary

A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.

Interventions

DIAGNOSTIC_TESTFundus Image Grading

The image is graded by a fully automated AI device

Sponsors

Artelus AI
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Ability to sign and date the informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age (≥)21 years of age or older 4. Diagnosed with diabetes mellitus as per criteria established by the World Health Organization (WHO) or the American Diabetes Association (ADA) 1. Hemoglobin A1c (HbA1c) ≥ 6.5% 2. Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) 3. Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)

Exclusion criteria

1. Persistent visual impairment in one or both eyes; 2. History of macular edema or retinal vascular (vein or artery) occlusion; 3. History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract surgery without complications; 4. Subject is contraindicated for fundus photography (for example, has light sensitivity); 5. Subject has contraindications for mydriatic medications or is unwilling or unable to dilate; 6. Subject is currently enrolled in an interventional study of an investigational device or drug for the same condition; or 7. Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or may result in ungradable clinical reference standard photographs 8. Subject falls into one of the below categories: * Adults unable to consent (individuals w/ impaired decision-making capacity) * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of AI GradeFrom time of arrival to completion of diagnostic tests, up to 8 hoursAI generated image grades are directly compared to a Human generated image grade

Countries

United States

Contacts

Primary ContactJeanne Champion, Primary Site Coordinator Oxford
Jeanne@ncophth.com9192347003
Backup ContactAdriana Valencia, Site Coordinator Raleigh
Adriana@ncophth.com9192347406

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026